NCT05675410 2026-04-13
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
21 trialsNCT05976763 2026-04-07
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07097363 2026-01-15
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Recruiting
NCT05455697 2025-12-18
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
Phase 1/2 Recruiting
NCT07278856 2025-12-12
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT06125028 2025-09-05
LYMFOR
Pentixapharm AG
Phase 3 Terminated
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT01359592 2025-06-17
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT05396118 2024-05-14
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Phase 2 Enrolling by invitation
NCT03226249 2023-06-02
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT02405078 2022-10-28
Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01004718 2021-05-18
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT00433459 2020-03-26
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Phase 3 Completed
NCT01476410 2020-02-17
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT02599194 2019-01-03
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
Phase 2 Completed
NCT00238368 2017-11-06
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02733887 2016-04-12
MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma
Guangxi Medical University
Phase NA Unknown
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn